Protagonist Therapeutics, Inc. (PTGX) Social Stream
PROTAGONIST THERAPEUTICS INC (PTGX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering PTGX.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-11-14 | 7 | $93 | $40 | $56.857 | $17.68 | 221.59% |
2021-11-15 | 7 | $93 | $40 | $58.285 | $17.68 | 229.67% |
2022-01-27 | 7 | $93 | $40 | $59 | $17.68 | 233.71% |
2022-03-02 | 8 | $93 | $40 | $58.5 | $17.68 | 230.88% |
2022-04-25 | 8 | $93 | $40 | $58 | $17.68 | 228.05% |
2022-04-26 | 8 | $93 | $40 | $56.75 | $17.68 | 220.98% |
2022-05-05 | 8 | $93 | $30 | $51.75 | $17.68 | 192.7% |
2022-05-06 | 8 | $70 | $30 | $47.625 | $17.68 | 169.37% |
2022-05-09 | 8 | $70 | $30 | $46.875 | $17.68 | 165.13% |
2022-05-17 | 8 | $70 | $30 | $43.75 | $17.68 | 147.45% |
2022-07-21 | 6 | $70 | $30 | $44.166 | $17.68 | 149.81% |
2022-08-05 | 6 | $70 | $30 | $44.285 | $17.68 | 150.48% |
2022-08-25 | 7 | $50 | $21 | $37.285 | $17.68 | 110.89% |
2022-09-28 | 7 | $50 | $21 | $36 | $17.68 | 103.62% |
2022-11-09 | 6 | $50 | $21 | $37 | $17.68 | 109.28% |
2023-01-17 | 6 | $45 | $21 | $34.166 | $17.68 | 93.25% |
2023-03-08 | 4 | $45 | $31 | $35.833 | $17.68 | 102.68% |
2023-03-16 | 5 | $45 | $31 | $36.666 | $17.68 | 107.39% |
2023-03-20 | 5 | $45 | $29 | $35.666 | $17.68 | 101.73% |
2023-05-08 | 5 | $38 | $29 | $33.8 | $17.68 | 91.18% |
2023-05-12 | 5 | $38 | $30 | $34 | $17.68 | 92.31% |
2023-05-25 | 5 | $40 | $31 | $36 | $17.68 | 103.62% |
2023-07-03 | 5 | $49 | $31 | $37.8 | $17.68 | 113.8% |
2023-08-04 | 6 | $49 | $35 | $39 | $17.68 | 120.59% |
The Trend in the Analyst Price Target
PTGX's average price target has moved down $7.88 over the prior 15 months.
PTGX reports an average of 146.1% for its upside potential over the past 44 weeks.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2022-09-28 | 7 | 50 | 21 | 36.000 | 8.81 | 308.63% |
2023-01-17 | 6 | 45 | 21 | 34.166 | 11.65 | 193.27% |
2023-03-16 | 5 | 45 | 31 | 36.666 | 23.15 | 58.38% |
2023-06-25 | 5 | 49 | 31 | 37.800 | 27.61 | 36.91% |
2023-07-03 | 5 | 49 | 31 | 37.800 | 22.31 | 69.43% |
PTGX Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
PTGX's average broker recommendation rating improved by 0 over the prior 153 days.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- PROTAGONIST THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 2576.3% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, PROTAGONIST THERAPEUTICS INC's variance in analysts' estimates is lower than -2159.84% of them.
- PROTAGONIST THERAPEUTICS INC's number of analysts covering the stock is greater than 1195.91% of stocks in the mid market cap category.
- PROTAGONIST THERAPEUTICS INC's average analyst price target is higher than 2063.27% of Pharmaceutical Products stocks.
Stocks similar to PROTAGONIST THERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RETA, AXSM, and BPMC.
View All Top Stocks by Price Target
What is the outlook for PTGX? Use POWR Ratings for clearer insight into price direction.